EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Intravenous non-specific immunoglobulins as adjunctive therapy for invasive Streptococcus pyogenes infection: an eleven-year retrospective study

Laura Caeiro-Martínez iD, David Brandariz-Núñez iD, María Sandra Albiñana-Pérez iD, Enrique Alemparte-Pardavila, Mónica Mourelo-Fariña iD, José María Gutiérrez-Urbón iD, Luis Margusino-Framiñán iD

Revista Española de Quimioterapia · 27.03.2026 · 39 (2) · 125

DOI: 10.37201/req/125.2026 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Revista Española de Quimioterapia, online erschienen am 19.03.2026. Verfasst von Laura Caeiro-Martínez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department/Service, A Coruña University Hospital (CHUAC), A Coruña, Spain. laura.caeiro.martinez@sergas.es. Hauptthemen laut MEDLINE: Streptococcal Infections, Immunoglobulins, Intravenous, Streptococcus pyogenes. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Adjunctive intravenous non-specific immunoglobulin (IVIG) is used in the management of streptococcal toxic shock syndrome, although supporting evidence remains limited. The primary objective of this study was to describe the use of IVIG in patients with invasive Streptococcus pyogenes infection. Materials and methods: We conducted a retrospective observational study over 11 years, including patients diagnosed with invasive S. pyogenes infection who received at least one dose of IVIG as adjunctive therapy.

Results

Twenty-three patients were included, with a mean age of 63.2 ± 16.3 years; 47.8% were male. Most patients (73.9%) developed septic shock and STSS, requiring admission to intensive care units. The mean Sequential Organ Failure Assessment (SOFA) score was 9.1 ± 4.9. High-dose IVIG (2.0 ± 0.2 g/kg) was administered promptly, with a mean time to first infusion of 0.26 ± 0.47 days from admission. In-hospital mortality was 21.7% overall and 29.4% among STSS patients. Non-survivors had significantly higher disease severity and were more likely to develop hepatic dysfunction and require continuous renal replacement therapy (CRRT). Two patients (8.7%) experienced IVIG-related adverse events, both of which were mild.

Conclusion

Early and standardized high-dose IVIG administration, in combination with prompt targeted antibiotic therapy and intensive supportive care, was associated with mortality rates similar to, or lower than, those previously reported. Initial disease severity, hepatic dysfunction, and need for CRRT were identified as predictors of mortality. IVIG demonstrated a favorable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcal InfectionsImmunoglobulins, IntravenousStreptococcus pyogenesHumansRetrospective StudiesMaleMiddle AgedFemaleShock, SepticHospital MortalityAnti-Bacterial AgentsTreatment Outcome

Stichwörter der Autor:innen

Intravenous immunoglobulinsStreptococcal toxic shock syndromeStreptococcus pyogenesToxic shock syndrome

Substanzen

Immunoglobulins, IntravenousAnti-Bacterial Agents

Autor:innen und Institutionen

  • Pharmacy Department/Service, A Coruña University Hospital (CHUAC), A Coruña, Spain. laura.caeiro.martinez@sergas.es.
  • Pharmacy Department/Service, A Coruña University Hospital (CHUAC), A Coruña, Spain.
  • Critical Care Unit, A Coruña University Hospital (CHUAC), A Coruña, Spain.
  • Research Group of Hospital Pharmacy, Biomedical Research Institute A Coruña (INIBIC), A Coruña University Hospital (CHUAC), SERGAS, A Coruña University (UDC), A Coruña, Spain.

ORCID-Profile: Laura Caeiro-Martínez, David Brandariz-Núñez, María Sandra Albiñana-Pérez, Mónica Mourelo-Fariña, José María Gutiérrez-Urbón, Luis Margusino-Framiñán

Zitieren

APA

Caeiro-Martínez, L., Brandariz-Núñez, D., Albiñana-Pérez, M. S., Alemparte-Pardavila, E., Mourelo-Fariña, M., Gutiérrez-Urbón, J. M., & Margusino-Framiñán, L. (2026). Intravenous non-specific immunoglobulins as adjunctive therapy for invasive Streptococcus pyogenes infection: an eleven-year retrospective study. Revista Española de Quimioterapia, 39(2), 125. https://doi.org/10.37201/req/125.2026

Vancouver

Caeiro-Martínez L, Brandariz-Núñez D, Albiñana-Pérez MS, Alemparte-Pardavila E, Mourelo-Fariña M, Gutiérrez-Urbón JM, et al. Intravenous non-specific immunoglobulins as adjunctive therapy for invasive Streptococcus pyogenes infection: an eleven-year retrospective study. Revista Española de Quimioterapia. 2026;39(2):125. doi:10.37201/req/125.2026

BibTeX
@article{CaeiroMartnez2026,
  author = {Caeiro-Martínez, Laura and Brandariz-Núñez, David and Albiñana-Pérez, María Sandra and Alemparte-Pardavila, Enrique and Mourelo-Fariña, Mónica and Gutiérrez-Urbón, José María and Margusino-Framiñán, Luis},
  title = {Intravenous non-specific immunoglobulins as adjunctive therapy for invasive Streptococcus pyogenes infection: an eleven-year retrospective study},
  journal = {Revista Española de Quimioterapia},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {125},
  doi = {10.37201/req/125.2026}
}
Kostenlos starten →